Literature DB >> 26085169

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

N Oreshkova1, L Spel2, R P M Vloet3, P J Wichgers Schreur3, R J M Moormann1, M Boes2, J Kortekaas4.   

Abstract

Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8(+) T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26085169      PMCID： PMC4524072          DOI： 10.1128/JVI.01105-15

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  14 in total

1.  Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Authors:  Itaru Anraku; Tracey J Harvey; Richard Linedale; Joy Gardner; David Harrich; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  A novel viral system for generating antigen-specific T cells.

Authors:  Timothy P Moran; Martha Collier; Karen P McKinnon; Nancy L Davis; Robert E Johnston; Jonathan S Serody
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

4.  DC-SIGN as a receptor for phleboviruses.

Authors:  Pierre-Yves Lozach; Andreas Kühbacher; Roger Meier; Roberta Mancini; David Bitto; Michèle Bouloy; Ari Helenius
Journal:  Cell Host Microbe       Date:  2011-07-21       Impact factor: 21.023

5.  An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Authors:  Michael A Morse; Amy C Hobeika; Takuya Osada; Peter Berglund; Bolyn Hubby; Sarah Negri; Donna Niedzwiecki; Gayathri R Devi; Bruce K Burnett; Timothy M Clay; Jonathan Smith; H Kim Lyerly
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

6.  Efficacy of three candidate Rift Valley fever vaccines in sheep.

Authors:  J Kortekaas; A F G Antonis; J Kant; R P M Vloet; A Vogel; N Oreshkova; S M de Boer; B J Bosch; R J M Moormann
Journal:  Vaccine       Date:  2012-03-24       Impact factor: 3.641

7.  Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells.

Authors:  Thijs W H Flinsenberg; Ewoud B Compeer; Dan Koning; Mark Klein; Femke J Amelung; Debbie van Baarle; Jaap Jan Boelens; Marianne Boes
Journal:  Blood       Date:  2012-10-23       Impact factor: 22.113

8.  Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.

Authors:  Martin Schlee; Andreas Roth; Veit Hornung; Cristina Amparo Hagmann; Vera Wimmenauer; Winfried Barchet; Christoph Coch; Markus Janke; Aleksandra Mihailovic; Greg Wardle; Stefan Juranek; Hiroki Kato; Taro Kawai; Hendrik Poeck; Katherine A Fitzgerald; Osamu Takeuchi; Shizuo Akira; Thomas Tuschl; Eicke Latz; Janos Ludwig; Gunther Hartmann
Journal:  Immunity       Date:  2009-07-02       Impact factor: 31.745

9.  Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.

Authors:  Karen A Herd; Tracey Harvey; Alexander A Khromykh; Robert W Tindle
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

10.  A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells.

Authors:  Nicolas Le May; Zeyni Mansuroglu; Psylvia Léger; Thibaut Josse; Guillaume Blot; Agnès Billecocq; Ramon Flick; Yves Jacob; Eliette Bonnefoy; Michèle Bouloy
Journal:  PLoS Pathog       Date:  2008-01       Impact factor: 6.823
View more
  2 in total

1.  Using RVFV as a Vector Platform for the Expression of Ruminant Disease Antigens.

Authors:  Sandra Moreno; Belén Borrego; Alejandro Brun
Journal:  Methods Mol Biol       Date:  2022

2.  Nonspreading Rift Valley Fever Virus Infection of Human Dendritic Cells Results in Downregulation of CD83 and Full Maturation of Bystander Cells.

Authors:  Nadia Oreshkova; Paul J Wichgers Schreur; Lotte Spel; Rianka P M Vloet; Rob J M Moormann; Marianne Boes; Jeroen Kortekaas
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.